The association of gout with sleep disorders: a cross-sectional study in primary care

BMC Musculoskeletal Disorders

Christian D Mallen¹  Richard Hayward¹  Sara Muller¹  Edward Roddy¹ 

[1] Arthritis Research UK Primary Care Centre, Keele University, Keele, UK

关键词: Metabolic syndrome X;    General practice;    Apnea;    Sleep;    Gout;   

Others  :  1132999
DOI  :  10.1186/1471-2474-14-119

 received in 2012-05-22, accepted in 2013-04-01,  发布年份 2013

【 摘 要 】

Background

Both gout and sleep apnoea are associated with the metabolic syndrome. Hyperuricaemia is also prevalent in sleep apnoea syndrome. The objective of this study was to examine the association between gout and sleep apnoea and other sleep disorders.

Methods

Data were taken from a validated database of general practice records from nine practices in the UK between 2001 and 2008. People consulting for gout were identified via Read codes and each matched with four controls for age, gender, practice and year of gout consultation. Sleep problems and confounding comorbidities were also identified via Read codes. Medications were identified through a linked database of prescription records. The association between gout and sleep disorders was assessed using a logistic regression model, adjusting for ischaemic heart disease, hypertension, diabetes mellitus and diuretic use.

Results

1689 individuals with gout were identified and each successfully matched to four controls. Amongst those with gout, the prevalence of any sleep problem was 4.9%, sleep problems other than sleep apnoea 4.2%, and sleep apnoea 0.7%, compared to 3.5%, 3.2% and 0.3% respectively in controls. Gout was associated with any sleep problem (odds ratio (OR) 1.44; 95% confidence interval (CI) 1.11, 1.87), sleep problems other than sleep apnoea (OR 1.36; 95% CI 1.03, 1.80), and sleep apnoea (OR 2.10; 95% CI 1.01, 4.39). On multivariable analysis, gout remained significantly associated with any sleep problem (OR 1.39; 95% CI 1.06, 1.81) and sleep problems other than sleep apnoea (OR 1.37; 95% CI 1.03, 1.82), however the association with sleep apnoea was attenuated (OR 1.48, 95% CI 0.70, 3.14).

Conclusions

Gout and sleep problems appear to be associated and clinicians should be aware of the co-existence of these two conditions. Larger prospective epidemiological studies are required to explore causality.

【 授权许可】

   
2013 Roddy et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Annemans L, Spaepen E, Gaskin M, Bonnemaire M, Malier V, Gilbert T, Nuki G: Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000–2005. Ann Rheum Dis 2008, 67:960-966.
• [2]Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Schumacher HR Jr, Saag KG: Gout epidemiology: results from the UK general practice research database, 1990–1999. Ann Rheum Dis 2005, 64:267-272.
• [3]Choi HK, Ford ES, Li C, Curhan G: Prevalence of the metabolic syndrome in patients with gout: the third national health and nutrition examination survey. Arthritis Rheum 2007, 57:109-115.
• [4]Choi HK, Atkinson K, Karlson EW, Curhan G: Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med 2005, 165:742-748.
• [5]Fam AG: Gout, diet, and the insulin resistance syndrome. J Rheumatol 2002, 29:1350-1355.
• [6]Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, Tuttle KR, Rodriguez-Iturbe B, Herrera-Acosta J, Mazzali M: Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003, 41:1183-1190.
• [7]Choi HK, Curhan G: Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007, 116:894-900.
• [8]Krishnan E, Baker JF, Furst DE, Schumacher HR: Gout and the risk of acute myocardial infarction. Arthritis Rheum 2006, 54:2688-2696.
• [9]Krishnan E, Svendsen K, Neaton JD, Grandits G, Kuller LH, MRFIT Research Group: Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med 2008, 168:1104-1110.
• [10]Kuo CF, See LC, Luo SF, Ko YS, Lin YS, Hwang JS, Lin CM, Chen HW, Yu KH: Gout: an independent risk factor for all-cause and cardiovascular mortality. Rheumatology (Oxford) 2010, 49:141-146.
• [11]Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S: The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993, 328:1230-1235.
• [12]Stradling JR, Crosby JH: Predictors and prevalence of obstructive sleep apnoea and snoring in 1001 middle aged men. Thorax 1991, 46:85-90.
• [13]Ram S, Seirawan H, Kumar SK, Clark GT: Prevalence and impact of sleep disorders and sleep habits in the United States. Sleep Breath 2010, 14:63-70.
• [14]Mold JW, Quattlebaum C, Schinnerer E, Boeckman L, Orr W, Hollabaugh K: Identification by primary care clinicians of patients with obstructive sleep apnea: a practice-based research network (PBRN) study. J Am Board Fam Med 2011, 24:138-145.
• [15]Lindberg E, Gislason T: Epidemiology of sleep-related obstructive breathing. Sleep Med Rev 2000, 4(5):411-433.
• [16]Sasanabe R, Banno K, Otake K, Hasegawa R, Usui K, Morita M, Shiomi T: Metabolic syndrome in Japanese patients with obstructive sleep apnea syndrome. Hypertens Res 2006, 29:315-322.
• [17]Parish JM, Adam T, Facchiano L: Relationship of metabolic syndrome and obstructive sleep apnea. J Clin Sleep Med 2007, 3:467-472.
• [18]Kono M, Tatsumi K, Saibara T, Nakamura A, Tanabe N, Takiguchi Y, Kuriyama T: Obstructive sleep apnea syndrome is associated with some components of metabolic syndrome. Chest 2007, 131:1387-1392.
• [19]Chou YT, Chuang LP, Li HY, Fu JY, Lin SW, Yang CT, Chen NH: Hyperlipidaemia in patients with sleep-related breathing disorders: prevalence & risk factors. Indian J Med Res 2010, 131:121-125.
• [20]West SD, Nicoll DJ, Stradling JR: Prevalence of obstructive sleep apnoea in men with type 2 diabetes. Thorax 2006, 61:945-950.
• [21]Shahar E, Whitney CW, Redline S, Lee ET, Newman AB, Javier Nieto F, O’Connor GT, Boland LL, Schwartz JE, Samet JM: Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med 2001, 163:19-25.
• [22]Pływaczewski R, Bednarek M, Jonczak L, Górecka D, Sliwińiski P: Hyperuricaemia in males with obstructive sleep apnoea (osa). Pneumonol Alergol Pol 2005, 73:254-259.
• [23]Pływaczewski R, Bednarek M, Jonczak L, Górecka D, Sliwiński P: Hyperuricaemia in females with obstructive sleep apnoea. Pneumonol Alergol Pol 2006, 74:159-165.
• [24]Ruiz García A, Sánchez Armengol A, Luque Crespo E, García Aguilar D, Romero Falcón A, Carmona Bernal C, Capote F: Blood uric acid levels in patients with sleep-disordered breathing. Arch Bronconeumol 2006, 42:492-500.
• [25]Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G: Alcohol intake and risk of incident gout in men: a prospective study. Lancet 2004, 363:1277-1281.
• [26]Mitler MM, Dawson A, Henriksen SJ, Sobers M, Bloom FE: Bedtime ethanol increases resistance of upper airways and produces sleep apneas in asymptomatic snorers. Alcohol Clin Exp Res 1988, 12:801-805.
• [27]Abrams B: Gout is an indicator of sleep apnea. Sleep 2005, 28:275.
• [28]Glantzounis GK, Tsimoyiannis EC, Kappas AM, Galaris DA: Uric acid and oxidative stress. Curr Pharm Des 2005, 11:4145-1451.
• [29]Sahebjani H: Changes in urinary uric acid excretion in obstructive sleep apnea before and after therapy with nasal continuous positive airway pressure. Chest 1998, 113:1604-1608.
• [30]Hasday JD, Grum CM: Nocturnal increase of urinary uric acid:creatinine ratio. A biochemical correlate of sleep-associated hypoxemia. Am Rev Respir Dis 1987, 135:534-538.
• [31]Jordan K, Clarke AM, Symmons DP, Fleming D, Porcheret M, Kadam UT, Croft P: Measuring disease prevalence: a comparison of musculoskeletal disease using four general practice consultation databases. Br J Gen Pract 2007, 57:7-14.
• [32]Porcheret M, Hughes R, Evans D, Jordan K, Whitehurst T, Ogden H, Croft P, North Staffordshire General Practice Research Network: Data quality of general practice electronic health records: the impact of a program of assessments, feedback, and training. J Am Med Inform Assoc 2004, 11:78-86.
• [33]Connecting for Health. http://www.connectingforhealth.nhs.uk/systemsandservices/data/uktc/readcodes webcite
• [34]Roddy E, Mallen CD, Hider SL, Jordan KP: Prescription and comorbidity screening following consultation for acute gout in primary care. Rheumatology (Oxford) 2010, 49:105-111.
• [35]Altman DG, Machin D, Bryant TN, Gardner MJ: Confidence Interval Analysis (CIA) Software. 2nd edition. London: BMJ Books; 2009.
• [36]StataCorp: Stata. Version 11.2. College Station: StataCorp; 2009.
• [37]Roddy E, Zhang W, Doherty M: Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations. Ann Rheum Dis 2007, 66:1311-1315.
• [38]Owens D, Whelan B, McCarthy G: A survey of the management of gout in primary care. Ir Med J 2008, 101:147-149.
• [39]Zhang W, Doherty M, Pascual E, Bardin T, Barskova V, Conaghan P, Gerster J, Jacobs J, Leeb B, Lioté F, McCarthy G, Netter P, Nuki G, Perez-Ruiz F, Pignone A, Pimentão J, Punzi L, Roddy E, Uhlig T, Zimmermann-Gòrska I, EULAR Standing Committee for International Clinical Studies Including Therapeutics: EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006, 65:1301-1311.
• [40]Wolfe F, Cathey MA: The misdiagnosis of gout and hyperuricemia. J Rheumatol 1991, 18:1232-1234.
• [41]Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Saag KG: Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD). Rheumatology (Oxford) 2005, 44:1038-1042.
• [42]Pal B, Foxall M, Dysart T, Carey F, Whittaker M: How is gout managed in primary care? A review of current practice and proposed guidelines. Clin Rheumatol 2000, 19:21-25.
• [43]Roth T, Bogan RK, Culpepper L, Doghramji K, Doghramji P, Drake C, Grauke JH, Knoepflmacher P, Sateia M, Silvershein D, Thorpy MJ: Excessive sleepiness: under-recognized and essential marker for sleep/wake disorder management. Curr Med Res Opin 2010, 26:S3-S24.
• [44]Kramer NR, Cook TE, Carlisle CC, Corwin RW, Millman RP: The role of the primary care physician in recognizing obstructive sleep apnea. Arch Intern Med 1999, 159:965-968.
• [45]Teran-Santos J, Jimenez-Gomez A, Cordero-Guevara J: The association between sleep apnea and the risk of traffic accidents. Cooperative Group Burgos-Santander. N Engl J Med 1999, 340:847-851.
• [46]West SD, McBeath HA, Stradling JR: Obstructive sleep apnoea in adults. BMJ 2009, 338:b1165.
• [47]Pepperell JC, Ramdassingh-Dow S, Crosthwaite N, Mullins R, Jenkinson C, Stradling JR, Davies RJ: Ambulatory blood pressure after therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised parallel trial. Lancet 2002, 359:204-210.